• VivoSim Labs posted royalty revenue of USD 131,000, up 10% year over year, with product revenue at no revenue after ending Mosaic operations in fiscal 2025.
• Other results swung to a USD 2.35 million expense from USD 10.13 million income, driven by a USD 2.7 million loss tied to the March 2026 offering.
• Research and development expense fell 17% to USD 4.19 million, while selling, general and administrative costs eased 4% to USD 7.43 million.
• Cash and cash equivalents dropped to USD 5 million at March 31, 2026, with operating cash outflow widening to USD 10.83 million.
• VivoSim pivoted to liver and intestinal toxicology services using 3D human tissue NAM models, citing 87.5% sensitivity and 100% specificity in May 2025 liver-tox data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-303316), on July 14, 2026, and is solely responsible for the information contained therein.